• Explore /
  • Poster
  • / ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).

ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).

Abstract Video & Slides Poster

Authors

Ian Flinn

Ian W. Flinn

Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN

Ian W. Flinn , Caron Alyce Jacobson , Loretta J. Nastoupil , Franck Morschhauser , Andrew Davies , Christian Buske , Paolo Corradini , Armando López Guillermo , Ran Reshef , Vinod Parameswaran , Alison Sehgal , Michael Timothy Tees , Christine Lui , Wei Xue , Sara Beygi , Nikolay Grechko , Pisita Bolsue , Alessandro Giovanetti , Christina Ann To , Myrna Nahas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Clinical Trial Registration Number

NCT05371093

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS7579)

DOI

10.1200/JCO.2023.41.16_suppl.TPS7579

Abstract #

TPS7579

Poster Bd #

129b

Abstract Disclosures

Similar Posters

First Author: Jason Westin

First Author: Paolo Strati

First Author: Larry D. Anderson, Jr

First Author: Sattva Swarup Neelapu